PolarityTE, Inc. (PTE) |
|
0.83 0.04 (5.02%)
|
01-27 15:57 |
|
Open: |
0.8055 |
Pre. Close: |
0.7903 |
|
High:
|
0.84 |
Low:
|
0.8027 |
|
Volume:
|
124,336 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:47:17 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 1.03 One year: 1.21 |
| Support: |
Support1: 0.72 Support2: 0.62 |
| Resistance: |
Resistance1: 0.88 Resistance2: 1.03 |
| Pivot: |
0.76  |
| Moving Average: |
MA(5): 0.79 MA(20): 0.74
MA(100): 0.75  MA(250): 3.01 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 87.3 %D(3): 84.5 |
| RSI: |
RSI(14): 64.1 |
| 52-week: |
High: 13 Low: 0.61 |
| Average Vol(K): |
3-Month: 198 (K) 10-Days: 46 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PTE ] has closed below upper band by 3.2%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.84 - 0.84 |
0.84 - 0.85 |
|
Low:
|
0.8 - 0.8 |
0.8 - 0.8 |
|
Close:
|
0.82 - 0.83 |
0.83 - 0.83 |
|
Company Description |
|
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah. |
Headline News |
Sat, 28 Jan 2023
Frasers Property Group toAcquire 50% Interest in NEX Suburban Retail Mall in Sinagpore - Sovereign Wealth Fund Institute
Sat, 28 Jan 2023
British soldier accused of terror offences appears in court - BBC
Fri, 27 Jan 2023
FengHe Fund Management Pte. Lt - GuruFocus.com
Thu, 26 Jan 2023
Pte Seán Rooney a 'genuine' man who will never be forgotten - Irish Examiner
Thu, 26 Jan 2023
Sports Titan Pte Ltd is Partnering Up with HokuApps to Re-Engineer ... - ACROFAN USA
Thu, 26 Jan 2023
Rivian Automotive, Inc. receives a $4.84 million investment from ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
6.1e+006 (%) |
|
% Held by Institutions
|
16.3 (%) |
|
Shares Short
|
761 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.771e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
592.4 |
|
Return on Equity (ttm)
|
-58.3 |
|
Qtrly Rev. Growth
|
1.86e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-63.26 |
|
EBITDA (p.s.)
|
4.46491e+006 |
|
Qtrly Earnings Growth
|
-6.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-26 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
0.39 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
209680 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2016-07-31 |
|
Ex-Dividend Date
|
2016-01-11 |
|
Your Ad Here
|
|
